A Phase I/II Double-Blind Controlled Trial to Determine the Safety and Immunogenicity of HIV-1 MN rgp160 Immuno AG Vaccine Therapy in HIV-Infected Individuals With Greater Than or Equal to 500/mm3 CD4+ T Cells and 200-400/mm3 CD4+ T Cells

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

Not specified

Study Completion Date

May 31, 1999

Conditions

HIV Infections

Interventions

DRUG

Ritonavir

BIOLOGICAL

gp160 Vaccine (Immuno-AG)

DRUG

Stavudine

DRUG

Didanosine

Trial Locations (1)

Stanford CRS, Stanford